These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9345383)

  • 21. Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis.
    Gidal BE; Wagner ML; Privitera MD; Dalmady-Israel C; Crismon ML; Fagan SC; Graves NM
    Ann Pharmacother; 1996 Nov; 30(11):1272-6. PubMed ID: 8913410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic developments in multiple sclerosis.
    Goodin DS
    Expert Opin Investig Drugs; 2000 Apr; 9(4):655-70. PubMed ID: 11060700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging treatments in multiple sclerosis.
    Schluep M; Bogousslavsky J
    Eur Neurol; 1997; 38(3):216-21. PubMed ID: 9363834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy of multiple sclerosis. Consensus and controversies].
    Hohlfeld R
    Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989
    [No Abstract]   [Full Text] [Related]  

  • 34. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis--Part 2. Treatment strategies.
    Olek MJ
    J Am Osteopath Assoc; 1999 Dec; 99(12):611-9. PubMed ID: 10641492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Kappos L; Kuhle J; Gass A; Achtnichts L; Radue EW
    J Neurol; 2004 Sep; 251 Suppl 5():v57-v64. PubMed ID: 15549357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.